Philogen announces the authorisation of a clinical trial with PHC-102 for the imaging of renal cell carcinoma.
Philogen announces the authorisation of a clinical trial with PHC-102 for the imaging of renal cell carcinoma.
Philogen announces research collaboration with Servier in the field of DNA-encoded chemistry.
Philogen announces research collaboration with Servier in the field of DNA-encoded chemistry.
Philogen S.p.A. enters into Multi-Target research agreement with Boehringer Ingelheim in the field of DNA-encoded chemistry.
Philogen S.p.A. enters into Multi-Target research agreement with Boehringer Ingelheim in the fiels of DNA-encoded chemistry.
Philogen S.p.A. announces participation to the ““FOCIS Annual Meeting 2017”, June 14 – 17, 2017, Chicago, USA
Philogen S.p.A. announces participation to the ““FOCIS Annual Meeting 2017”Philogen S.p.A. announces participation to the “5th Heidelberg Forum for Young Life Scientists”
Philogen S.p.A. announces participation to the “5th Heidelberg Forum for Young Life Scientists”, June 8 – 9, 2017, Heidelberg, GermanyPhilogen S.p.A announces the publication in the prestigious Chemistry: A European Journal
Philogen S.p.A announces the publication in the prestigious Chemistry: A European Journal of a communication entitled: "A specific and covalent JNK-1 ligand selected from an encoded self-assembling chemical library"
Philogen S.p.A. announces participation to the “CHI Immuno-Oncology Summit Europe”, March 20 – 24, 2017, London, UK
Philogen S.p.A. announces participation to the “CHI Immuno-Oncology Summit Europe”Philogen S.p.A. announces participation to the “7th annual World ADC Berlin meeting”
Philogen S.p.A. announces participation to the “7th annual World ADC Berlin meeting”, February 20 – 22, 2017, Berlin, GermanyPhilogen S.p.A. announces participation to the “PEGS Boston – The Essential Protein Engineering Summit (2017)”
Philogen S.p.A. announces participation to the “PEGS Boston – The Essential Protein Engineering Summit (2017)”, May 1 – 5, 2017, Boston, USA